1. Signaling Pathways
  2. JAK/STAT Signaling
    Stem Cell/Wnt
  3. STAT

STAT

STAT is a family of cytoplasmic protein that regulates many aspects of growth, survival and differentiation in cells. The transcription factors of this family are activated by Janus kinase and dysregulation of this pathway is frequently observed in primary tumours and leads to increased angiogenesis, enhanced survival of tumours and immunosuppression. Gene knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system and play a role in maintaining immune tolerance and tumour surveillance. STAT proteins were originally described as latent cytoplasmic transcription factors that require phosphorylation for nuclear retention. The unphosphorylated STAT proteins shuttle between cytosol and the nucleus waiting for its activation signal. Once the activated transcription factor reaches the nucleus, it binds to consensus DNA-recognition motif called gamma-activated sites (GAS) in the promoter region of cytokine-inducible genes and activates transcription of these genes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0193S1
    Artesunate-d4
    Inhibitor
    Artesunate-d4 is deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
    Artesunate-d<sub>4</sub>
  • HY-N0498R
    Nitidine chloride (Standard)
    Inhibitor
    Nitidine (chloride) (Standard) is the analytical standard of Nitidine (chloride). This product is intended for research and analytical applications. Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK and c-Src/FAK associated signaling pathway. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway.
    Nitidine chloride (Standard)
  • HY-N6953R
    Garcinone D (Standard)
    Activator
    Garcinone D (Standard) is the analytical standard of Garcinone D (HY-N6953). This product is intended for research and analytical applications. Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of CDK2/CyclinE1 (IC50 for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer.
    Garcinone D (Standard)
  • HY-108417
    Debio 0617B
    Inhibitor
    Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors.
    Debio 0617B
  • HY-178140
    STAT3-IN-47
    Inhibitor
    STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma.
    STAT3-IN-47
  • HY-Q43097
    Hsp110-STAT3 PPI-IN-1
    Inhibitor
    Row174336 (compound 29) is a potent inhibitor of Hsp110-STAT3 interaction that shows antiproliferative activity against HPAEC cell line, with the IC50 of 22.67 μM.
    Hsp110-STAT3 PPI-IN-1
  • HY-W1113770
    STAT6-IN-8
    Inhibitor
    STAT6-IN-8 (Compound 9) is a STAT6 inhibitor with potential anti-inflammatory and anti-allergic effects. STAT6-IN-8 can be used for the study of STAT6-associated diseases, including inflammatory diseases (atopic dermatitis, bronchial asthma) and allergic diseases (allergic rhinitis, chronic sinusitis).
    STAT6-IN-8
  • HY-157847
    phospho-STAT3-IN-2
    Phospho-STAT3-IN-2 (compound 4D) is a STAT3 inhibitor that effectively inhibits STAT3 phosphorylation. phospho-STAT3-IN-2 can significantly reduce tumor volume in mouse xenograft tumor models without drug toxicity to other organs and tissues.
    phospho-STAT3-IN-2
  • HY-N11501
    7-epi-Isogarcinol
    Inhibitor
    7-epi-Isogarcinol is a polycyclic polyprenylated acylphloroglucinol (PPAP), with moderate antiproliferative activity. 7-epi-Isogarcinol blocks STAT3 signaling pathway, to induce apoptosis and inhibit cell migration.
    7-epi-Isogarcinol
  • HY-N0242R
    Fraxinellone (Standard)
    Inhibitor
    Fraxinellone (Standard) is the analytical standard of Fraxinellone. This product is intended for research and analytical applications. Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
    Fraxinellone (Standard)
  • HY-N0735R
    Phellodendrine chloride (Standard)
    Inhibitor
    Phellodendrine chloride (Standard) is the analytical standard of Phellodendrine chloride (HY-N0735). Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.
    Phellodendrine chloride (Standard)
  • HY-148692A
    (E/Z)-OSM-SMI-10B
    Inhibitor
    (E/Z)-OSM-SMI-10B a derivative of OSM-SMI-10. (E/Z)-OSM-SMI-10B significantly reduces OSM-induced STAT3 phosphorylation in cancer cells upon co-incubation with OSM (Oncostatin M).
    (E/Z)-OSM-SMI-10B
  • HY-P10113
    STAT3-IN-23
    Inhibitor
    STAT3-IN-23 (PY*LKTK) is a potent STAT3 inhibitor.
    STAT3-IN-23
  • HY-175650
    STAT6-IN-9
    Inhibitor
    STAT6-IN-9 (Compound 6) is a potent STAT6 inhibitor, with an EC50 value of 4 nM. STAT6-IN-9 efficiently blocks the STAT6 activation process mediated by the IL-13-IL-13 receptor/IL-4 receptor pathway. STAT6-IN-9 inhibits CCL17 secretion with an IC50 value of 4.6 nM. STAT6-IN-9 can be used in the research of various chronic inflammatory diseases mediated by STAT6, such as allergies, asthma, chronic obstructive pulmonary disease.
    STAT6-IN-9
  • HY-N2959R
    Brevilin A (Standard)
    Inhibitor
    Brevilin A (Standard) is the analytical standard of Brevilin A. This product is intended for research and analytical applications. Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC50= 10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy.
    Brevilin A (Standard)
  • HY-175010
    STAT3-IN-44
    Inhibitor
    STAT3-IN-44 is a potent STAT3 inhibitor with IC50s of 1.84 (C6 cells) and 4.81 μM (A549 cells). STAT3-IN-44 inhibits STAT3 phosphorylation, downregulates Bcl-2, and upregulates Caspase-3 to promote late-stage apoptosis. STAT3-IN-44 significantly suppresses tumor cell proliferation and migration. STAT3-IN-44 can be used for the study of cancers such as glioma and lung cancer.
    STAT3-IN-44
  • HY-100610
    S3I-1757
    Inhibitor
    S3I-1757 is a STAT3 inhibitor. S3I-1757 inhibits the phosphorylation and dimerization of STAT3. S3I-1757 can be used for the research of STAT3 hyperactive cancers such as melanoma.
    S3I-1757
  • HY-N13294
    Cernuumolide J
    Inhibitor
    Cernuumolide J (TMJ-105) is an JAK2/STAT3 inhibitor. Cernuumolide J induces G2/M phase arrest and apoptosis in HEL leukemia cells by downregulating the phosphorylation of JAK2, STAT3, and Erk, and activating the phosphorylation of JNK and p38 MAPK. Cernuumolide J inhibits HEL leukemia cell growth in a time- and concentration-dependent manner, with an IC50 value of 1.79 μM. Cernuumolide J can be used for research in the field of anti-cancer therapy.
    Cernuumolide J
  • HY-N0202R
    Atractylenolide II (Standard)
    Inhibitor
    Atractylenolide II (Standard) is the analytical standard of Atractylenolide II. This product is intended for research and analytical applications. Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity.
    Atractylenolide II (Standard)
  • HY-151559
    Zn-DPA-maytansinoid conjugate 1
    Modulator
    Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an "inflamed hot tumor" .
    Zn-DPA-maytansinoid conjugate 1
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.